(INZY) Inozyme Pharma - Performance -16% in 12m
Compare INZY with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-78.56%
#126 in Peer-Group
Rel. Strength
31.14%
#5240 in Stock-Universe
Total Return 12m
-15.96%
#61 in Peer-Group
Total Return 5y
-77.48%
#85 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 6.00 USD |
| 52 Week Low | 0.82 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 97.17 |
| Buy/Sell Signal +-5 | -1.40 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: INZY (-16%) vs XBI (-13.2%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| ABBV NYSE AbbVie |
6.84% | 15.6% | 146% | 75.7 | 15 | 0.39 | -26.0% | 14.2% |
| GILD NASDAQ Gilead Sciences |
3.25% | 66.1% | 80.1% | 22.9 | 13.8 | 0.23 | 28.0% | -3.71% |
| UTHR NASDAQ United Therapeutics |
8.95% | 12.5% | 161% | 12.4 | 11 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
0.02% | -11% | 42.6% | 23.9 | 13 | 0.9 | 0.60% | 41% |
| LONN SW Lonza |
3.89% | 12.4% | 20.3% | 63.4 | 34.7 | 1.27 | 2.20% | -12.5% |
| BIM PA Biomerieux |
5.4% | 27.4% | -8.66% | 32.5 | 25.2 | 1.52 | -38.5% | -25.1% |
| KMDA NASDAQ Kamada |
6.72% | 32.6% | -8.16% | 24.8 | 24.4 | 0.97 | 48.1% | 3.93% |
| NBIX NASDAQ Neurocrine Biosciences |
19.8% | -14.2% | 1.4% | 39.2 | 23.6 | 0.27 | 18.7% | -34.3% |
Performance Comparison: INZY vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for INZY
| Total Return (including Dividends) | INZY | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 303.31% | 5.06% | 13.42% |
| 3 Months | 216.00% | -13.48% | -2.55% |
| 12 Months | -15.96% | -13.24% | 11.09% |
| 5 Years | -77.48% | -23.08% | 109.60% |
| Trend Score (consistency of price movement) | INZY | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 79.5% | -39.2% | 93.5% |
| 3 Months | 20.2% | -69.2% | -14.5% |
| 12 Months | -82.2% | -62.5% | 46.8% |
| 5 Years | -72.2% | -53.9% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | #1 | 283.89% | 255.58% |
| 3 Month | #2 | 265.25% | 224.28% |
| 12 Month | #63 | -3.13% | -24.35% |
| 5 Years | #82 | -68.27% | -88.42% |
FAQs
Does Inozyme Pharma (INZY) outperform the market?
No,
over the last 12 months INZY made -15.96%, while its related Sector, the SPDR S&P Biotech (XBI) made -13.24%.
Over the last 3 months INZY made 216.00%, while XBI made -13.48%.
Performance Comparison INZY vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
INZY vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 193.4% | 289.9% | 48% | -27% |
| US NASDAQ 100 | QQQ | 193.7% | 284.9% | 44.9% | -29% |
| German DAX 40 | DAX | 190.1% | 290.3% | 21.3% | -44% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 193.2% | 298.2% | 47.3% | -25% |
| Hongkong Hang Seng | HSI | 193% | 288.4% | 35.4% | -27% |
| India NIFTY 50 | INDA | 192.5% | 301.4% | 44.5% | -18% |
| Brasil Bovespa | EWZ | 194.5% | 293.5% | 39.3% | -11% |
INZY vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 192.4% | 288.9% | 42.4% | -39% |
| Consumer Discretionary | XLY | 194.7% | 286% | 47.9% | -36% |
| Consumer Staples | XLP | 189.9% | 302.6% | 44.9% | -23% |
| Energy | XLE | 196.3% | 299.9% | 61% | -6% |
| Financial | XLF | 193.9% | 293.2% | 45.8% | -37% |
| Health Care | XLV | 190.4% | 304.1% | 54.7% | -7% |
| Industrial | XLI | 192.1% | 287.9% | 45.6% | -31% |
| Materials | XLB | 191.8% | 295.2% | 54.1% | -11% |
| Real Estate | XLRE | 192.5% | 300.4% | 52.1% | -26% |
| Technology | XLK | 194.7% | 281.3% | 48.3% | -24% |
| Utilities | XLU | 190.1% | 296.3% | 46.1% | -31% |
| Aerospace & Defense | XAR | 191.9% | 287.1% | 37.8% | -44% |
| Biotech | XBI | 188.7% | 298.3% | 62.7% | -3% |
| Homebuilder | XHB | 195.7% | 295.7% | 65.4% | -6% |
| Retail | XRT | 192.8% | 290.2% | 51.9% | -16% |
INZY vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 194.3% | 305% | 54.5% | -5% |
| Natural Gas | UNG | 195.4% | 297.7% | 35.2% | -3% |
| Gold | GLD | 188.3% | 306.4% | 22.9% | -52% |
| Silver | SLV | 188.3% | 300.9% | 38% | -20% |
| Copper | CPER | 191.9% | 305.3% | 34.1% | -9% |
INZY vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 194.2% | 305.3% | 51.9% | -11% |
| iShares High Yield Corp. Bond | HYG | 193.1% | 300.9% | 44.8% | -24% |